Target Price | $43.25 |
Price | $38.26 |
Potential |
13.04%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target Collegium Pharmaceutical, Inc. 2025 .
The average Collegium Pharmaceutical, Inc. target price is $43.25.
This is
13.04%
register free of charge
$50.00
30.68%
register free of charge
$37.00
3.29%
register free of charge
|
|
A rating was issued by 5 analysts: 3 Analysts recommend Collegium Pharmaceutical, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Collegium Pharmaceutical, Inc. stock has an average upside potential 2025 of
13.04%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 566.77 | 619.48 |
22.17% | 9.30% | |
EBITDA Margin | 57.29% | 64.54% |
30.43% | 12.65% | |
Net Margin | 7.36% | 13.70% |
242.69% | 86.24% |
5 Analysts have issued a sales forecast Collegium Pharmaceutical, Inc. 2024 . The average Collegium Pharmaceutical, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Collegium Pharmaceutical, Inc. EBITDA forecast 2024. The average Collegium Pharmaceutical, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Collegium Pharmaceutical, Inc. Analysts have issued a net profit forecast 2024. The average Collegium Pharmaceutical, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | 1.29 | 2.63 |
274.32% | 103.88% | |
P/E | 14.57 | |
EV/Sales | 2.45 |
3 Analysts have issued a Collegium Pharmaceutical, Inc. forecast for earnings per share. The average Collegium Pharmaceutical, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Collegium Pharmaceutical, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Collegium Pharmaceutical, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.